| Pre-treatment Mean (SD) | Post-treatment Mean (SD) | 12 months Mean (SD) | F value | effect size partial Eta 2 |
---|---|---|---|---|---|
ITT (N = 32) | Â | Â | Â | Â | Â |
GAF | 60.62(6.36) | 66.41(6.74)a | 71.22(9.16)b, c | 21.44*** | 0.32 |
SF-36 PCS | 42.23 (8.88) | 48.21 (9.78)a | 46.97 (9.34)b | 6.71** | 0.13 |
   Physical functioning | 76.87(16.84) | 84.53 (14.67)a | 84.53 (14.11)b | 8.28*** | 0.15 |
   Role physical | 21.88(39.53) | 60.16 (45.73)a | 59.38 (40.54)b | 11.39*** | 0.20 |
   Bodily pain | 65.84(22.56) | 70.73 (25.29) | 74.06 (24.06) | 1.87 | 0.04 |
   General health | 39.78(14.92) | 51.13 (20.59)a | 49.91 (19.64)b | 5.19** | 0.10 |
SF-36 MCS | 26.16 (9.70) | 33.59 (11.20)a | 38.34 (11.63)b | 15.32*** | 0.25 |
   Vitality | 26.41(14.66) | 40.31 (19.10)a | 43.75 (19.76)b | 12.59*** | 0.22 |
   Social functioning | 44.84(21.91) | 60.55 (23.14)a | 68.75 (25.79)b | 10.51*** | 0.19 |
   Role emotional | 13.54(31.52) | 37.50 (42.12)a | 54.17 (43.79)b | 13.07*** | 0.22 |
   Mental health | 38.13(16.51) | 51.63 (18.16)a | 55.83 (18.80)b | 13.18*** | 0.22 |
Completers (N = 20) | Â | Â | Â | Â | Â |
GAF | 60.24 (6.86) | 66.48 (6.40)a | 73.81 (7.29)b, c | 25.99*** | 0.48 |
SF-36 PCS | 43.80 (8.48) | 50.32 (7.88)a | 48.18 (7.28) | 5.10** | 0.15 |
   Physical functioning | 80.25(13.13) | 89.50 (9.02)a | 89.00 (7.88)b | 12.31*** | 0.31 |
   Role physical | 21.25(40.78) | 57.50 (47.37)a | 56.25 (38.79)b | 5.75** | 0.17 |
   Bodily pain | 66.60 (24.30) | 73.28 (27.40) | 76.30 (26.75) | 1.34 | 0.05 |
   General health | 39.55 (16.17) | 55.90 (22.06)a | 54.10 (21.19)b | 6.94** | 0.27 |
SF-36 MCS | 25.23 (9.77) | 33.78 (11.06)a | 40.56 (10.71)b, c | 13.91*** | 0.33 |
   Vitality | 25.50 (13.66) | 42.25 (16.58)a | 47.25 (17.66)b | 10.78*** | 0.28 |
   Social functioning | 48.00 (21.86) | 61.87 (26.12) | 73.13 (29.32)b | 8.69** | 0.24 |
   Role emotional | 13.33 (33.16) | 40.00 (45.37) | 63.33 (45.76)b, c | 11.23*** | 0.29 |
   Mental health | 34.80 (16.68) | 52.00 (16.57)a | 57.60 (17.38)b | 15.00** | 0.35 |